Isosorbide

05/01/1995 - "Efficacy of long-term administration of isosorbide for Ménière's disease."
01/01/1982 - "Treatment of Ménière's disease with isosorbide."
09/25/2021 - "Isosorbide (ISO) is an effective hyperosmotic agent that can be administrated orally and is used as a therapeutic agent for brain pressure drop, glaucoma, and Meniere's disease. "
11/01/2016 - "This prospective study was to explore the diagnostic utility of a dehydration test, administering oral isosorbide, which has been used to treat Meniere's disease (MD). "
11/01/2016 - "Is dehydration test using isosorbide useful in Meniere's disease?"

05/01/1993 - "Eighteen patients died (9 in the isosorbide-treated group), 6 due to bleeding. "
05/01/2008 - "beta-Blockers+/-isosorbide-5-mononitrate and band ligation are effective in preventing recurrent bleeding and both can be used. "
01/01/1993 - "[Isosorbide-5-mononitrate in the prevention of digestive hemorrhage in cirrhosis: randomized study]."
01/01/2000 - "In cirrhotic patients with acute gastro-oesophageal variceal bleeding, addition of isosorbide 5-mononitrate to somatostatin does not improve therapeutic efficacy, induces more adverse effects, and should not be used."
01/01/2000 - "Somatostatin plus isosorbide 5-mononitrate versus somatostatin in the control of acute gastro-oesophageal variceal bleeding: a double blind, randomised, placebo controlled clinical trial."

03/01/2001 - "Isosorbide 5-mononitrate (5-ISMN) was evaluated in normal dogs and dogs with congestive heart failure (CHF) in a randomized, blinded, and placebo-controlled study. "
01/01/2007 - "[Endothelial dysfunction in patients with chronic heart failure, and possibilities of its correction with isosorbide-5-mononitrates]."
01/01/1987 - "Acute and chronic use of isosorbide 5-mononitrate in patients with heart failure."
09/01/1975 - "These data demonstrate that the objectives of therapy in congestive heart failure, namely improved forward output and decreased ventricular filling pressures, can be achieved without metabolic deterioration by using sublingual isosorbide. "
02/01/2006 - "To evaluate sublingual isosorbide administration as a test of reversibility of pulmonary hypertension in heart failure. "

01/01/2023 - "Intratympanic administration of isosorbide resolves endolymphatic hydrops faster than oral ingestion. "
01/01/2004 - "Time course of dehydrating effects of isosorbide on experimentally induced endolymphatic hydrops in guinea pigs."
01/01/1995 - "Changes in hearing were studied in 145 ears (103 patients) with endolymphatic hydrops before and after an 8-week administration of isosorbide. "
11/01/2021 - "Effects of Intratympanic Injection of Isosorbide on the Vestibular Function of Animal Models of Endolymphatic Hydrops."
01/01/2023 - "In the hydrops group, 50% isosorbide slightly reduced endolymphatic hydrops; 65% flattened Reissner's membrane, and 70% slightly concaved it toward the basilar membrane. "

02/01/1990 - "The effects of oral isosorbide 5-mononitrate on mortality following acute myocardial infarction: a multicentre study."
01/01/1987 - "Controlled study of the haemodynamic effects of isosorbide 5-mononitrate in acute myocardial infarction."
09/01/2022 - "The entire metabolic changes between short- and long-term administration of CDDP were profiled by UPLC-Q-TOF-MS. In addition, the metabolic regulatory network of CDDP administration against myocardial infarction rats was also compared with those of a typical chemical drug isosorbide 5-mononitrate (ISMN). "
06/01/1995 - "The plasma concentrations of isosorbide 5-mononitrate (5-ISMN) administered in an extended-release form to patients with acute myocardial infarction."
07/01/1990 - "The effects of oral isosorbide 5-mononitrate on mortality following acute myocardial infarction."